NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Shares Down 6.8% – Time to Sell?

Posted by Donna Armstrong on Dec 29th, 2025

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY – Get Free Report) dropped 6.8% on Monday . The stock traded as low as $4.48 and last traded at $4.52. Approximately 81,391 shares changed hands during mid-day trading, a decline of 96% from the average daily volume of 2,084,421 shares. The stock had previously closed at $4.85.

NovaBay Pharmaceuticals Stock Up 0.1%

The stock has a market capitalization of $612.03 million, a PE ratio of -0.49 and a beta of 0.57. The firm has a 50 day moving average price of $1.83 and a 200 day moving average price of $1.41.

Hedge Funds Weigh In On NovaBay Pharmaceuticals

Several hedge funds have recently modified their holdings of NBY. Ground Swell Capital LLC bought a new position in shares of NovaBay Pharmaceuticals in the third quarter valued at approximately $25,000. Apollon Wealth Management LLC bought a new position in NovaBay Pharmaceuticals in the 3rd quarter valued at $35,000. Finally, C2C Wealth Management LLC grew its stake in NovaBay Pharmaceuticals by 78.2% in the 2nd quarter. C2C Wealth Management LLC now owns 98,000 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 43,000 shares during the period. Institutional investors own 23.25% of the company’s stock.

About NovaBay Pharmaceuticals

(Get Free Report)

NovaBay Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, non-antibiotic anti-infective products designed to regulate the innate immune response. Leveraging its proprietary Aganocide® Technology, the company’s synthetic antimicrobial compounds target and neutralize pathogens without contributing to antibiotic resistance. NovaBay’s research and development efforts concentrate on ophthalmic, dermatological and wound care applications, aiming to address unmet needs in infection control and inflammation management.

The company’s primary commercial products include Avenova®, an eyelid and lash cleaning solution indicated for managing chronic blepharitis and meibomian gland dysfunction, and NeutroPhase®, a pure hypochlorous acid wound and skin cleanser used in acute and chronic wound irrigation.